1. 1) Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med., 339, 1448–1456 (1998).
2. 2) La L, Wang L, Qin F, Jiang J, He S, Wang C, Li Y. Zhen-wu-tang ameliorates adenine-induced chronic renal failure in rats: regulation of the canonical Wnt4/beta-catenin signaling in the kidneys. J. Ethnopharmacol., 219, 81–90 (2018).
3. 3) Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet, 383, 1831–1843 (2014).
4. 4) Sanai T, Okuda S, Motomura K, Onoyama K, Fujishima M. Effect of phosphate binders on the course of chronic renal failure in rats with focal glomerular sclerosis. Nephron, 51, 530–535 (1989).
5. 5) Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-Lanckman MM, Vanherweghem JL. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J. Am. Soc. Nephrol., 13, 431–436 (2002).